- Home
- ARQT vs ADEA Comparison
ARQT vs ADEA Comparison
Compare ARQT & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ADEA
- Stock Information
- Founded
- ARQT 2016
- ADEA 1990
- Country
- ARQT United States
- ADEA United States
- Employees
- ARQT N/A
- ADEA N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ADEA Computer Software: Prepackaged Software
- Sector
- ARQT Health Care
- ADEA Technology
- Exchange
- ARQT Nasdaq
- ADEA Nasdaq
- Market Cap
- ARQT 1.7B
- ADEA 1.6B
- IPO Year
- ARQT 2020
- ADEA N/A
- Fundamental
- Price
- ARQT $15.99
- ADEA $15.52
- Analyst Decision
- ARQT Strong Buy
- ADEA Strong Buy
- Analyst Count
- ARQT 7
- ADEA 4
- Target Price
- ARQT $19.00
- ADEA $19.50
- AVG Volume (30 Days)
- ARQT 1.8M
- ADEA 551.8K
- Earning Date
- ARQT 08-06-2025
- ADEA 08-05-2025
- Dividend Yield
- ARQT N/A
- ADEA 1.37%
- EPS Growth
- ARQT N/A
- ADEA 80.44
- EPS
- ARQT N/A
- ADEA 0.74
- Revenue
- ARQT $263,464,999.00
- ADEA $378,674,000.00
- Revenue This Year
- ARQT $61.83
- ADEA $10.01
- Revenue Next Year
- ARQT $36.55
- ADEA $4.42
- P/E Ratio
- ARQT N/A
- ADEA $20.98
- Revenue Growth
- ARQT 99.50
- ADEA 5.47
- 52 Week Low
- ARQT $8.03
- ADEA $10.59
- 52 Week High
- ARQT $17.75
- ADEA $17.46
- Technical
- Relative Strength Index (RSI)
- ARQT 56.88
- ADEA 66.17
- Support Level
- ARQT $15.43
- ADEA $14.40
- Resistance Level
- ARQT $17.29
- ADEA $15.39
- Average True Range (ATR)
- ARQT 0.97
- ADEA 0.58
- MACD
- ARQT 0.06
- ADEA 0.13
- Stochastic Oscillator
- ARQT 63.70
- ADEA 95.29
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.